anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Intrauterine fetal growth restriction (IUGR) is an affliction of a disparaging spectrum, placental insufficiency being the major inciting pathology. The resultant fetal hypoglycemia is alleviated by intravenous hypertonic D-glucose 25-50% maternal supplements, by improving the Vmax of placental transfer for D-glucose, in accordance with Michaelis-Menten model of substrate transfer. Fetal normoglycemia so restored in turn surprisingly improves fetal hypoxia, hypercapnia, hyperlacticemia, acidosis, hypertriglyceridemia, oliguria/hydromnios, and the fetal nutrient/mineral/vitamin acquisition. The list being phenomenal can only convince an inquiring reader by a biochemical sojourn into the aquatic world of the fetus, herein described. Maternal carbohydrate-predominant IUGR diet with maximal amounts of vitamin/mineral supplements are highly beneficial. Transamniotic isotonic D-glucose supplements via minimally invasive suprapubic extraperitonial pelvic approach and amniotomy (Sumathi Paturu's technique), with a subcutaneously implanted pregnancy port (SIPP) catheter is the additional therapy advocated.
As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin converting enzyme inhibitors, including enalapril maleate, may be associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death (see PRECAUTIONS, Drug Interactions).

In clinical studies in hypertensive patients with unilateral or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine were observed in 20 percent of patients. These increases were almost always reversible upon discontinuation of enalapril and/or diuretic therapy. In such patients renal function should be monitored during the first few weeks of therapy.

Some patients with hypertension or heart failure with no apparent preexisting renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when enalapril maleate has been given concomitantly with a diuretic. This is more likely to occur in patients with preexisting renal impairment. Dosage reduction and/or discontinuation of the diuretic and/or enalapril maleate may be required.

Evaluation of patients with hypertension or heart failure should always include assessment of renal function (see DOSAGE AND ADMINISTRATION).
Diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.

In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis.

As an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present, and to diminish the patient’s recall of the procedures. (See WARNINGS.)

Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; stiff-man syndrome; and tetanus.

Diazepam is a useful adjunct in status epilepticus and severe recurrent convulsive seizures.

Diazepam is a useful premedication (the I.M. route is preferred) for relief of anxiety and tension in patients who are to undergo surgical procedures. Intravenously, prior to cardioversion for the relief of anxiety and tension and to diminish the patient’s recall of the procedure.
A weakened ERA-strain of rabies virus which has been adapted to grow in pigs kidney tissue cells, is subjected to a sufficient number of passages in a Madin-Darby tissue culture of non-primary bovine kidney cells (MDBK-cells) until the antigentiy is sufficiently high. The MDBK-cells used are free from extraneous impurities by treatment in the customary way. They are dispersed in a nutrient medium, inoculated with the virus and cultured at 32-27 degrees C. until a confluent monolayer has formed. The virus is harvested using the usual freezing-thawing technique and the customary stabilisers are added. The vaccine is then freeze-dried. The live vaccine has a high antigenity in dogs, cats and cattle. The process does not use primary tissue cultures but a continuous cell line which obviates impurities. The vaccine produced is free from pathogenic effects.
Patients will be grouped to ClinOleic-based lipid parenteral nutrition regimen using ClinOleic or Structolipid-based lipid parenteral nutrition regimen using Structolipid. From day 0 to day 5, patients will not to receive any food or liquid oral or enteral nutrition. The goal of treatment is to deliver 25kcal/kg/day, 1.05g/kg/day amino acids, and 1.1g/kg/day lipid. The weight of patient calculated as ideal body weight. The patients will be allowed water based on the clinical judgment of the Investigator. From day 6 through the remainder of the study treatment period, liquid oral or enteral nutrition could be added to the study treatment. The intent is to supply the total calculated daily nutritional requirement with study treatment plus liquid oral or enteral nutrition. Liquid oral or enteral nutrition will be increased daily, as tolerated by the patient, with a concurrent reduction in study treatment, while still supplying the calculated daily nutritional requirement.
The invention relates to a medicament for treating cancer and application thereof, which belong to the field of chemical medicaments. The technical problem solved by the invention is to provide the medicament for treating cancer. The medicament for treating cancer comprises the following active components: trivalent V salts of phosphoric acid. Compared with a commercially available similar medicament, the medicament of the invention has an obviously lower cost, thereby reducing the economic burden of a patient. Clinical researches show that the medicament has no obvious side or toxic effect in use, and also cannot increase pain for the body of the patient. The medicament has a higher cure rate, provides a now selection for treating cancer, and has an extensive market prospect.
This clinical trial was conducted in a qualified clinical trial institution. Investigators will use Abdominal Aortic Aneurysm Stent Graft System manufactured by Lifetech Scientific (Shenzhen) Co., LTD. to treat patients with Infrarenal Abdominal Aortic Aneurysm. This is a Prospective, Multi-center, Objective Performance Criteria Clinical Trial. It is expected to submit to the ethics committee of the lead unit for review in March 2018, and complete the implantation of 156 patients in 22 centres nationwide within 12 months, and interim follow-up was conducted before discharge, 30 days after surgery, 6 months after surgery and 12 months after surgery, long-term follow-up will be performed at 24 months postoperatively, 36 months postoperatively, 48 months postoperatively and 60 months postoperatively.

This trial will evaluate whether the device reached the primary safety endpoint and primary efficacy endpoint through two primary endpoint indicators: the incidence of major adverse events (MAE) within 30 days and the success rate of abdominal aortic aneurysm treatment 12 months after surgery. This trail will evaluate whether the device reached the secondary safety endpoint and primary efficacy endpoint through several secondary endpoint indicators: Perioperative (intraoperative to postoperative 30 days) delivery related complications incidence rate (including the transabdominal surgery caused by intraoperative conveyors, the hemorrhage in the middle iliac artery, the hemorrhage in the femoral artery at the puncture site, the hematoma and the pseudoaneurysm), the incidence of acute lower limb ischemia before discharge and 30 days after surgery, all-cause mortality at 6 months, 12 months and 2-5 years after surgery, abdominal aortic aneurysm-related mortality at 6 months, 12 months and 2-5 years after surgery, the incidence of severe adverse events (SAE) at 6 months, 12 months and 2-5 years after surgery, the incidence of the device-related adverse events (AE) at 6 months, 12 months and 2-5 years after surgery, the incidence of type I or type III leakage at 6 months, 12 months after surgery, the incidence of displacement of Abdominal Aortic Aneurysm Stent at 6 months, 12 months after surgery and the incidence of conversion from abdominal aortic aneurysm treatment to open surgery or secondary surgery intervention at 6 months, 12 months and 2-5 years after surgery. According to the guidelines for clinical trials of aortic stent system, the sponsor will apply for CFDA listing registration after completing a 12-month primary endpoint assessment. According to the guidelines for clinical trials of aortic covered stent system, the sponsor will apply for CFDA listing registration after completing a 12-month primary endpoint assessment, and annually follow-up will be conducted until the fifth year for the long-term efficacy observation.
Dosing in this phase of the study consists of the first cycle of therapy (i.e., 28 days consisting of 3 weeks of treatment followed by 1 week with no study drug). The BTX-A51 starting dose for Cohort 1 is 1 mg, to be given 5 days per week (maximum weekly dose of 5 mg). Beginning with Cohort 2, doses are intended to be administered 3 days per week. Barring dose-limiting toxicity (DLT), sequential dose escalation of BTX-A51 is planned with up to a total of eight dose levels to a maximum of 21 mg (63 mg/week); on the basis of these an MTD will be identified. The numbers of participants and actual doses administered will be determined using a Bayesian optimal interval (BOIN) design to determine the DLTs and MTD of BTX-A51.
Single Chamber BFR (Delfi, Vancouver, Canada) training devices will be used for exercise and testing sessions (see attachment). Cuffs will be placed around the right and left proximal thigh. The LOP will be set at 60% immediately before exercise and will be applied during the entire exercise set (approximately 30-60 seconds in duration) in accordance with manufacturer specifications. The cuffs will maintain pressure during training and rest periods. The LOP will be decreased to 0% immediately after the set is completed.
Patients with latent hypothyroidism show an increased hormone status in TSH and a normal hormone status in fT4. A study has shown that osteopathic treatment had positive effects to some symptoms in patients with latent hypothyroidism. The study was using the pain inventory as the instrument to measure the effect. In this study we want to evaluate the effectiveness of the treatment on the hormone status (TSH, fT4) The intervention group will receive a neurological osteopathic stimulation over 5 weeks. A parallel control group will not receive any therapy.

A follow up blood screening (TSH, fT4) will be done. The results of both groups will be compared.
The objective of this study was to compare the value of one-, two- and three-dimensional computed tomography (CT) measurements for predicting the efficacy of a single session of extracorporeal shock wave lithotripsy (ESWL) in patients with a single ureteral stone. A total of 165 patients were included based on the inclusion and exclusion criteria. Different models were constructed using a combination of patients' clinical data and measurements obtained by manual sketching and automated extraction software. Multivariate logistic regression was used to develop the models. Receiver operating characteristic curves were used to assess the performance of the models. There was good interobserver agreement for all measurements in different dimensions (P < 0.001). We also found that hydronephrosis, the largest diameter, the largest area, volume, and mean CT value were significantly greater in the failure group than in the success group (P < 0.01). Furthermore, all sizes and CT measurement values were found to be independent predictors for predicting efficacy after one session of ESWL (P < 0.05). In addition, the multivariate logistic analysis showed that the area under the curve (AUC) for two-dimensional and three-dimensional measurements was superior to that of one-dimensional measurement (P < 0.01). However, when size alone was included as a measurable predictor, there was no significant difference in the AUC among the one-, two-, and three-dimensional measurements (P > 0.05). In summary, after adjusting for clinical data, two- and three-dimensional measurements combining ureteral stone size and CT values were found to be the best predictors of ESWL efficacy, and software-based three-dimensional measurements should be considered to avoid interobserver variability in clinical practice.
Tinea (pityriasis) versicolor is a non-contagious infection of the skin caused by Pityrosporum orbiculare (Malassezia furfur). This commensal organism is part of the normal skin flora. In susceptible individuals the condition is often recurrent and may give rise to hyperpigmented or hypopigmented patches on the trunk which may extend to the neck, arms and upper thighs. Treatment of the infection may not immediately result in restoration of pigment to the affected sites. Normalization of pigment following successful therapy is variable and may take months, depending on individual skin type and incidental skin exposure. The rate of recurrence of infection is variable.

Ketoconazole was not detected in plasma in 39 patients who shampooed 4-10 times per week for 6 months, or in 33 patients who shampooed 2-3 times per week for 3-26 months (mean: 16 months).

An exaggerated use washing test on the sensitive antecubital skin of 10 subjects twice daily for five consecutive days showed that the irritancy potential of ketoconazole shampoo, 2% was significantly less than that of 2.5% selenium sulfide shampoo.

A human sensitization test, a phototoxicity study, and a photoallergy study conducted in 38 male and 22 female volunteers showed no contact sensitization of the delayed hypersensitivity type, no phototoxicity and no photoallergenic potential due to ketoconazole shampoo, 2%.
Conventional Treatment Patients in this group will be given activity modification and home exercise program training, including stretching and eccentric strengthening exercises. Patients will be asked to perform the exercise treatment in 3 sets of 10 repetitions. Additionally, a splint will be recommended to rest the arm.
A method of purifying triterpenoid-based compound is described. A crude extract of Ganoderma is provided, wherein the crude extract of Ganoderma includes a first-type triterpenoid-based compound and a second-type triterpenoid-based compound. The first-type triterpenoid-based compound includes ganoderic acid A. The second-type triterpenoid-based compound includes ganoderic acid F and ganoderiol B. Next, simulated moving bed chromatography was used to separate triterpenoid-based compound from the crude extract of Ganoderma. By using the simulated moving bed chromatography, the first-type triterpenoid-based compound including ganoderic acid A may be separated from the second-type triterpenoid-based compound including ganoderic acid F and ganoderiol B in the crude extract of Ganoderma, hence forming triterpenoid-based compound with high purity.
All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
The invention relates to the use of a Xuebijing component for the preparation of a medicament for the regulation of sepsis. The components include at least one of naringenin, chlorogenic acid, albiflorin, paeoniflorin, ferulic acid ethyl ester, luteolin, quercetin, apigenin, and neocnidilide. Wherein at least one of naringenin, chlorogenic acid and albiflorin can regulate blood coagulation function, at least one of naringenin, albiflorin, chlorogenic acid, paeoniflorin and ferulic acid ethyl ester can regulate apoptosis, and at least one of luteolin, naringenin, quercetin, apigenin and neocnidilide can regulate immunity function. The uses include modulation of coagulation disorders of sepsis, apoptosis, and immune dysfunction. The inventor identifies part of substances capable of regulating sepsis in the Xuebijing through network pharmacology calculation prediction and experimental verification. In vitro verification experiments show that the substances can influence the detection indexes of the coagulation function, the apoptosis and the immune function of the sepsis.
PURPOSE: To provide a skin washing article good in use feeling, having high detergency and capable of discharging creamy foams good in shape retention. CONSTITUTION: This skin washing article is prepared by filling a detergent composition preferably containing 0.1-30wt.% of (A) a phosphoric acid ester- based surfactant of the formula (R<1> is a 5-13C hydrocarbon group; R<2> is a 5-11C hydrocarbon group, here, the sum total of the number of carbon atoms in R1 and R<2> is 12-22; X and X<2> are each H, an alkali metal, ammonium, a basic amino acid residue, an alkanolamine residue having a 2-3C hydroxyalkyl) and 1-50wt.% of (B) an anion surfactant, e.g. potassium laurate in a foam discharging container having a porous film (e.g. a sponge, a sintered body, a net). When 3-30wt.% polyol is added to the detergent composition, feeling becomes better in case of massaging with foams and moist feeling of the skin is good after washing out the detergent composition.  When 0.1-10wt.% ethanol is added, tin and creamy foams can be obtained and the detergency of the detergent composition is enhanced.
CHR-2845 is a novel type of histone deacetylase inhibitor (HDACi) for use in cancer that, in addition to having broad ranging anti-proliferative activity against transformed cells, is designed to have an increased therapeutic window against diseases which involve cells of the monocyte-macrophage lineage. There are several HDACi's in clinical development and one, SAHA (Vorinostat, Zolinza®), has recently been approved for use in the treatment of cutaneous T-cell lymphoma. CHR-2845 is a cell-permeant ester that is metabolised to give an active acid, CHR-2847, which selectively accumulates in monocytes and macrophages. This results in a 20-100 fold increase in anti-proliferative potency of CHR-2845 for monocytic over non-monocytic tumour cells. This selectivity should lead to an increased therapeutic window in haematological malignancies involving cells of the monocyte lineage (AML M4, AML M5 and CMML). In addition, there is increasing evidence that monocytes and macrophages associated with some haematological tumours (tumour-associated macrophages (TAMs)) are involved in supporting the growth and spread of the tumour. This clinical trial will focus on haematological and lymphoid malignancies with the intention of evaluating the safety and tolerability of CHR-2845. Additionally it will compare response in patients where monocytes/macrophages are important disease drivers, with the response in other patients. This will allow an early determination of the potential improvement in therapeutic window afforded by the monocyte/macrophage directed HDACi activity.
In pregnant women, aztreonam crosses the placenta and enters the fetal circulation.

Developmental toxicity studies in pregnant rats and rabbits with daily doses of aztreonam up to 1,800 and 1,200 mg/kg, respectively, revealed no evidence of embryotoxicity or fetotoxicity or teratogenicity. These doses, based on body surface area, are 2.2- and 2.9-fold greater than the MRHD for adults of 8 g per day. A peri/postnatal study in rats revealed no drug-induced changes in any maternal, fetal, or neonatal parameters. The highest dose used in this study, 1,800 mg/kg/day, is 2.2 times the MRHD based on body surface area.

There are no adequate and well-controlled studies of aztreonam on human pregnancy outcomes. Because animal reproduction studies are not always predictive of human response, aztreonam should be used during pregnancy only if clearly needed.
PROBLEM TO BE SOLVED: To obtain a package of a mixed agrochemical composition having improved stability. SOLUTION: A package of a mixed agrochemical composition containing highly concentrated pesticidal formulations including a water-soluble pesticide or a plant growth regulator (e.g. a herbicide, a salt of glyphosate) and a solid water-insoluble pesticide or plant growth regulator (e.g. a herbicide, flumioxazin), is obtained. The water-soluble pesticidal formulation or the plant growth regulator is dissolved in a continuous water phase and the water-insoluble pesticide or the solid plant growth regulator is dispersed in water phase. The solid particles are tightly enveloped individually or plurally with a barrier layer comprising a water immiscible organic solvent and/or an emulsifier having hydrophilic-lipopilic balance(HLB) of <= about 15. The composition includes, according to circumstances, a thickener (e.g. hydrophilic colloidal silica) dispersed in aqueous phase.  The composition manifests a higher resistance against sedimentation of solid particles and/or a higher resistance against chemical degradation of water-insoluble pesticides or plant growth regulators compared with the same composition excluding the barrier layer or the organic solvent.
The name of the present invention is a rhizoma fagopyri dibotryis jerusalem artichoke polysaccharide tablet belonging to the technical field of health care products. The rhizoma fagopyri dibotryis jerusalem artichoke polysaccharide tablet mainly is prepared by compounding jerusalem artichoke polysaccharide as a main raw material, and a rhizoma fagopyri dibotryis extract, a rhizoma fagopyri dibotryis solution and other materials, grinding, sieving, granulating and tabletting. The rhizoma fagopyri dibotryis jerusalem artichoke polysaccharide tablet aims to adjust blood sugar, reduce blood fat, clear heat and remove toxicity, disperse wind, remove phlegm, invigorate the circulation of blood, dissipate stasis, and invigorate the spleen to eliminate dampness. The product causes no harm to the human body, has health care effect, and is easy to take. The rhizoma fagopyri dibotryis jerusalem artichoke polysaccharide tablet mainly comprises 50-70g of the jerusalem artichoke polysaccharide, 30-50g of the rhizoma fagopyri dibotryis extract, 35-50ml of the rhizoma fagopyri dibotryis solution, 5-7g of disintegrant sodium carboxymethyl starch, magnesium stearate lubricant accounting for 0.1-0.2% (wt) of the total mass; 20-45ml by volume of adhesive PVPK30 ethanol solution with the concentration of 0.5-1.5% (wt). Preparation steps are as follows: 1, extraction and purification of the jerusalem artichoke polysaccharide, 2, rhizoma fagopyri dibotryis active ingredient extraction, and 3, preparation of the rhizoma fagopyri dibotryis jerusalem artichoke polysaccharide tablet.